Xu Xiu-li, Huang Yuan
Yao Xue Xue Bao. 2016 Aug;51(8):1250-6.
To study the synergistic anti-tumor effects of doxorubicin and axitinib in combination, and investigate the underlying mechanism, we performed the MTT cytotoxic assay and tumor spheroids inhibition to investigate in vitro using A549 cells. The cell internalization, cell cycle distribution and DNA ladder experiments were performed to study the synergistic mechanisms. A549 xenograft was established in nude mice and adopted to study the in vivo anti-tumor effect of doxorubicin and axitinib. Results showed that combination of doxorubicin and axitinib exerted significantly higher cytotoxicity than each single drug, and induced a synergistic effect on tumor spheroids growth inhibition. The combination achieved the highest tumor growth suppression in vivo in the A549 xenograft. The combination of axitinib and doxorubicin exhibited the best anti-tumor effects both in vitro and in vivo than each single drug.
为研究阿霉素和阿昔替尼联合使用的协同抗肿瘤作用，并探究其潜在机制，我们进行了MTT细胞毒性试验和肿瘤球抑制试验，以利用A549细胞进行体外研究。进行细胞内化、细胞周期分布和DNA梯状条带实验以研究协同机制。在裸鼠中建立A549异种移植模型，用于研究阿霉素和阿昔替尼的体内抗肿瘤作用。结果显示，阿霉素和阿昔替尼联合使用比每种单一药物具有显著更高的细胞毒性，并对肿瘤球生长抑制产生协同作用。该联合用药在A549异种移植模型中实现了体内最高的肿瘤生长抑制。与每种单一药物相比，阿昔替尼和阿霉素联合使用在体外和体内均表现出最佳的抗肿瘤效果。
